Healthcare Fraud Enforcement Trends

by Manatt, Phelps & Phillips, LLP
Contact

Manatt, Phelps & Phillips, LLP

Editor’s Note: In just the first year of the Trump administration, healthcare faced an avalanche of change. The disputes arising from the flood of new developments encompass both legal and regulatory challenges—and are being played out in both courts and government agencies. Ultimately, they may trigger significant shifts in existing healthcare law. In a recent webinar, Manatt explored the game-changing trends and cases to watch in 2018. In a new series summarizing the program, Manatt examines how the transforming healthcare environment is affecting litigation—and remapping the legal and regulatory landscapes. Last month, in part 1 of the series, we looked at conscience rights and civil rights in healthcare. In part 2, below, we focus on the False Claims Act (FCA) and fraud and abuse enforcement trends.

To view the full webinar free on demand, click here. To download a free copy of the webinar presentation, click here.
_______________________________________

The Current State of Play: Healthcare Fraud Prosecutions Remain a Priority

Despite the uncertainty and divisiveness in the political realm, there is one issue that appears to be bipartisan—the government’s continued focus on prosecuting healthcare fraud. Comments and speeches from government officials, including Attorney General Jeff Sessions and Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, make it clear that the government has made it a high priority to root out fraud in federal programs and recover money lost due to fraud or false claims. Recent activities demonstrate the government’s determination to ferret out and prosecute healthcare fraud.

In June 2016, the Department of Justice (DOJ) announced a nationwide sweep in 36 districts resulting in charges against more than 300 individuals—including 61 doctors, nurses and other licensed professionals—for healthcare fraud schemes, involving $900 million in false billings. In July 2017, the DOJ announced the largest healthcare fraud takedown in history, involving 41 districts; $1.3 billion in false billings; and charges against 400 defendants, including 115 doctors, nurses and other healthcare professionals.

In fact, the DOJ has reported that during the fiscal year ending September 2017, it obtained more than $3.7 billion in settlements and judgments from civil cases that involved fraud and false claims against the government. The majority of that money— $2.4 billion—involved the healthcare industry, including drug companies, hospitals, pharmacies, laboratories and physicians. The DOJ also reported that, in 2017, relators—private individuals who file enforcement actions on behalf of the government—filed 492 lawsuits related to healthcare fraud. The false claims brought by both the government and relators are based on alleged off-label marketing, kickbacks, Stark violations, upcoding, double billing and lack of medical necessity claims.

There’s no question that the DOJ views healthcare fraud as a major drain on Medicare resources. All signs point to the DOJ continuing to target drug companies, hospitals, medical device companies and physician practices. Individuals and smaller physician groups, however, are not immune to efforts to combat fraud and abuse.

Major Enforcement Trends

1. Individual Accountability

Sally Yates became a familiar name in 2017 when, as acting U.S. Attorney General, she announced that the DOJ would not defend President Trump’s immigration and refugee ban. In the healthcare industry, however, Ms. Yates is better known for her memo titled “Individual Accountability for Corporate Wrongdoing,” more commonly called the “Yates memo.” Drafted in September 2015, the memo directed U.S. attorneys to target individual wrongdoers, including corporate executives, involved in corporate crimes. The memo is significant because it directed government prosecutors to focus on individuals, regardless of their ranks or their roles, in cases of corporate wrongdoing. It even included incentives to ensure entities assisted in the government’s efforts to hold individuals accountable.

Although Ms. Yates is no longer serving as U.S. attorney general, her memo is still being followed—and several FCA settlements imposing individual liability have caused healthcare executives to take notice. For example, the owner of Life Care Centers of America paid $145 million to settle allegations that Life Care caused skilled nursing facilities to submit false claims for rehabilitation therapy services. This trend will undoubtedly continue. As current Attorney General Jeff Sessions confirmed in an April 2017 interview, the DOJ is looking forward to charging individuals responsible for corporate misbehavior and mismanagement.

2. Improper Financial Arrangements

Another trend gaining strength is government investigations of improper financial arrangements, particularly violations of the Anti-Kickback Statute and the Stark Law. Several recent examples reflect this growing trend. For example:

  • In June 2017, the owners and operators of an acute care hospital in Los Angeles agreed to pay $42 million to settle allegations that they violated the FCA by engaging in financial arrangements with referring physicians in violation of the Anti-Kickback Statute and Stark Law.
  • In May 2017, two Southwest Missouri healthcare practitioners agreed to pay the federal government $34 million to settle allegations that they violated the FCA by submitting false claims to Medicare for chemotherapy services rendered to patients referred by oncologists whose compensation was based, in part, on a formula that improperly took the value of their referrals into account.
  • In September 2017, Galena Biopharma, Inc., agreed to pay $7.55 million for paying doctors kickbacks to prescribe a fentanyl-based drug. (The physicians who received the kickbacks are in prison following a jury trial.)

3. Combating the Opioid Epidemic

The trend that has received the most press and attention is the government’s focus on combating the opioid epidemic. Pharmaceutical manufacturers and wholesale distributors have recently seen the most activity, with lawsuits filed by almost every state, multiple municipalities and several Native American tribal nations—all seeking to recover funds that they have expended to deal with opioid abuse. Over the past year, the federal government has expanded its focus beyond manufacturers to pursue prescribers and healthcare providers who have submitted claims to federal healthcare programs for opioid prescriptions. These efforts include investigations under the FCA and administrative actions, in addition to traditional criminal actions.

For example, last summer, the DOJ and the U.S. Department of Health & Human Services Office of the Inspector General (OIG) engaged in the largest-ever healthcare fraud enforcement action by the Medicare Fraud Strike Force, involving more than 400 charged defendants in over 41 federal districts. Of those charged, 120 were charged for their role in prescribing and distributing opioids and other dangerous narcotics.

In addition, on August 7, 2017, the DOJ announced the formation of the Opioid Fraud and Abuse Detection Unit. In connection with the Unit’s formation, the DOJ assigned experienced prosecutors in 12 opioid “hotspots”—Alabama, California, Florida, Kentucky, Maryland, Michigan, Nevada, North Carolina, Ohio, Pennsylvania, Tennessee and West Virginia—to focus exclusively on prosecuting opioid-related healthcare fraud. The Attorney General also stated that there would be a surge in Drug Enforcement Administration (DEA) agents and investigators focused on pharmacies and prescribers who are dispensing unusual and disproportionate amounts of opioids.

More recently, on February 27, 2018, the DOJ announced the creation of the Prescription Interdiction and Litigation (PIL) Task Force. Among other things, PIL is tasked with examining state and local government lawsuits against opioid manufacturers to determine what assistance, if any, federal law can provide. With the Trump administration’s public health emergency orders, the government is likely to continue increasing its enforcement activities against opioid abusers.

4. Viability of FCA Cases Alleging Medical Necessity

Finally, another growing trend is FCA cases grappling with the question of objective falsity, particularly in the context of FCA claims where the alleged falsity is premised on a lack of medical necessity in connection with the medical services provided. In these cases, the government or the relator alleges that a provider has violated the FCA by billing the federal government for services that are not medically necessary.

One way to establish that a particular service is not medically necessary is to rely on experts to explain why that service is not a medical necessity. However, several recent cases have ruled that a mere difference of opinion between physicians, without more, is not enough to establish falsity under the FCA. In United States ex rel. Polukoff v. St. Mark’s Hospital et al. (No. 16-cv-00304. 2017 U.S. Dist. LEXIS 8187 (Jan. 19, 2017, D. Utah)), a federal district court in Utah considered whether claims submitted by a physician could be deemed “objectively false” based on alleged noncompliance with industry standards. The court concluded that allegations that a doctor failed to comply with an industry standard for medical care do not satisfy the objective falsity standard and do not render false the physician’s certification that he or she believed that the services were “medically indicated and necessary for the health of the patient.”

In this case, the relator, Dr. Polukoff, alleged that Dr. Sorensen had performed unnecessary medical procedures—specifically, patent foramen ovale (PFO) closures, which are used to close the wall between the two upper chambers of the heart. The relator alleged that Dr. Sorensen and the two hospitals where the procedures were being performed were fraudulently billing the government for costs associated with the PFO closures. The relator argued that PFO closures were reasonable and medically necessary only in highly limited circumstances, such as where there was a history of stroke. Medicare had not issued a National Coverage Determination (NCD) for PFO closures or otherwise indicated circumstances under which it would pay for such procedures. However, the relator attempted to introduce medical guidelines issued by the American Heart Association, as well as physician testimony about the circumstances under which the procedure would have been appropriate.

The defendants, however, moved to dismiss the case for failure to prove that an objectively false claim had been submitted to the government. The court agreed with the defendants, finding that the relator failed as a matter of law to show that the defendants knowingly made an objectively false representation to the government. The court went on to hold that “[o]pinions, medical judgments, and ‘conclusions about which reasonable minds may differ cannot be false’ for the purposes of an FCA claim.”

The court further held that the relator’s assertion that some of the procedures were not reasonable or necessary because they were performed on patients who had not suffered a stroke was a subjective medical opinion that could not be proven objective. The Polukoff case joins several others in rejecting FCA claims premised on lack of medical necessity or other matters of scientific judgment.

FCA Risks in a Managed Care Environment

FCA risks are somewhat different in a managed care environment. In a conventional FCA complaint, a provider has submitted a claim directly either to Medicare or Medicaid, and the relator or the government alleges that the claim was false. For example, the provider may have been alleged to have billed for a service that was not provided or not medically necessary, making the fraud relatively easy to understand.

With so much healthcare in the United States, however, now taking place through managed care, the financial incentives, and therefore the possibilities for fraud, are differently aligned. In Medicare or Medicaid managed care, a private managed care entity receives a fixed capitation payment from the government for each member that it covers. Providers then bill the managed care entity. Therefore, even if a provider is falsely billing a managed care entity, that would not necessarily change how much the government pays.

This does not mean, however, that managed care is immune from FCA litigation. Instead, it means that FCA litigation can be more complex. For example, an increasing number of managed care entities in Medicaid, Medicare and commercial markets are receiving risk-adjusted payments, with managed care plans receiving more money from the government as they enroll sicker patients.

In addition, more and more health plans and providers have contracting arrangements under which they share risk. Therefore, while, traditionally, providers had an interest in billing as much as possible and plans had an interest in reducing billings as much as possible, providers and plans are now more aligned. Both have an interest in managing the utilization of healthcare while also maximizing the revenue that the plan is receiving from the government, since risks and rewards are shared. This can give rise to incentives for providers or plans to improperly make patients appear to be higher risk than they actually may be or to inappropriately limit utilization.

The only significant appellate decision in this area is United States ex rel. Swoben v. United Healthcare Ins. Co. in the Ninth Circuit in 2016. The case was brought against a Medicare Advantage plan and its contracted providers, who had a risk-sharing arrangement with the plan. The allegations included that there had been one-sided, retrospective chart reviews that identified underreporting of diagnosis scores relevant to risk adjustment but ignored overreporting of diagnosis scores.

On a motion to dismiss, the district court had dismissed the FCA case. The Ninth Circuit, however, reversed the district court on the motion to dismiss and ruled that if there were one-sided chart reviews, that would be sufficient to allege an FCA complaint. The allegations against several of the named defendants weren’t specific enough for the case to go forward, however. Instead, the case proceeded only against United, the Medicare Advantage insurer, and one contracted provider group that was specifically alleged to be involved in the retrospective chart reviews.

Health plans and providers looking to the case for guidance on compliance should note that the court was very interested in any indicators there might have been that there were problems with the chart reviews and coding. A high error score on a risk adjustment data validation (RADV) audit can be evidence that it would not be possible in good faith to certify the accuracy of the data. A high RADV score alone, however, should not be enough to allege an FCA violation.

At about the same time as the Swoben case, Universal Health Services v. United States ex rel. Escobar was decided by the Supreme Court. Escobar affirmed that the implied false certification of compliance theory can be a basis for liability under the FCA when a defendant submitting a claim makes specific representations about the goods or services provided but fails to disclose noncompliance with material statutory, regulatory or contractual requirements that make those representations misleading. In other words, noncompliance could be a basis for an FCA action—but only if that noncompliance is material to whether the provider gets paid.

On remand from the Ninth Circuit, the Justice Department filed a new complaint in intervention, but the district court again dismissed, this time for failure to adequately plead materiality in light of Escobar. While the Justice Department declined to file an amended complaint, a related case has proceeded to district court. In that case, United States ex. rel. Poehling v. UnitedHealth Group, Inc. (C.D. Cal. Feb. 12, 2016), the court dismissed the claims related to the plan’s alleged false certifications of compliance but permitted claims to proceed regarding alleged invalid diagnosis codes that had been submitted.

Takeaways

When submitting data to the government that is going to be the basis for payment, it is critical to be diligent. There is likely to be greater scrutiny in an environment where provider and payer interests are aligned. As a result, there is the need for strong internal compliance programs and audit reviews to ensure that the entity submitting the data is confident in its accuracy—and that any reviews have “looked both ways” to uncover both upcoding and undercoding.

Manatt has conducted compliance reviews of health plans’ risk adjustment and provider contracting processes to identify areas for improvement to minimize these risks. Health plan compliance efforts vary widely. Given increased interest in this area from regulators and plaintiffs, health plan and provider compliance and legal staff should review their processes for risk adjustment, data collection and validation, and plan-provider risk-based contracting.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Manatt, Phelps & Phillips, LLP | Attorney Advertising

Written by:

Manatt, Phelps & Phillips, LLP
Contact
more
less

Manatt, Phelps & Phillips, LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.